215380 — Woojung BIO Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Woojung BIO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	37,344	31,238	46,918	38,616	43,200
Cost of Revenue
Gross Profit	5,299	5,877	6,727	6,290	12,686
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	42,649	34,764	50,286	44,882	40,880
Operating Profit	-5,305	-3,526	-3,368	-6,266	2,320
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-10,568	-1,926	-1,866	-5,054	225
Provision for Income Taxes
Net Income After Taxes	-10,879	-1,926	-1,880	-5,054	225
Net Income Before Extraordinary Items
Net Income	-10,879	-1,926	-1,880	-5,054	225
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-10,879	-1,926	-1,880	-5,054	-410
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-939	-156	-99.8	-256	-61.4
Dividends per Share